GSK senior managers acquire shares under reward plan

GSK plc (GSK) reported that multiple senior managers and one person closely associated with a manager acquired Ordinary Shares of 31¼ pence each under the company’s Share Reward Plan.

Rhea-AI Filing Summary

GSK plc (GSK) reported that multiple senior managers and one person closely associated with a manager acquired Ordinary Shares of 31¼ pence each under the company’s Share Reward Plan. Each participant acquired 7 partnership shares and 7 matching shares, totaling 14 Ordinary Shares each at £18.0296 per share on September 9, 2026, on the London Stock Exchange.

Key Figures

Share price: £18.0296 per Ordinary Share Partnership shares per person: 7 Ordinary Shares Matching shares per person: 7 Ordinary Shares +2 more

5 metrics

Share price £18.0296 per Ordinary Share Acquisitions under GSK’s Share Reward Plan on September 9, 2026

Partnership shares per person 7 Ordinary Shares Allocated as partnership shares to each listed individual

Matching shares per person 7 Ordinary Shares Allocated as matching shares to each listed individual

Total shares per person 14 Ordinary Shares Aggregated volume reported for each transaction at £18.0296

Transaction date September 9, 2026 Date of all reported Share Reward Plan acquisitions

Key Terms

Person Discharging Managerial Responsibilities (PDMR), person closely associated (PCA), Share Reward Plan, Ordinary shares of 31 ¼ pence each, +1 more

5 terms

Person Discharging Managerial Responsibilities (PDMR) regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

A person discharging managerial responsibilities (PDMR) is a senior executive or board-level individual who regularly has access to confidential, price‑sensitive information about a company. For investors, identifying PDMRs matters because their stock trades must be reported and are closely watched as potential signals of insider knowledge or leadership confidence — like watching team captains’ moves to gauge the team’s prospects.

person closely associated (PCA) regulatory

"Details of PDMR/person closely associated with them (‘PCA’)"

Share Reward Plan financial

"Acquisition of Ordinary Shares under the Company’s Share Reward Plan"

Ordinary shares of 31 ¼ pence each financial

"Description of the financial instrument | Ordinary shares of 31 ¼ pence each"

LEI regulatory

"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GSK (GSK) report in this Form 6-K?

GSK reported that several senior managers and one person closely associated with a manager each acquired 14 Ordinary Shares under the company’s Share Reward Plan on September 9, 2026 at a price of £18.0296 per share on the London Stock Exchange.

Which GSK (GSK) executives acquired shares in this disclosure?

Executives acquiring shares include Lynn Baxter, Julie Brown, James Ford, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse, and Victoria Whyte, along with Neil Falkingham as a person closely associated with Lynn Baxter.

What price and volume per leg were reported for the GSK (GSK) share acquisitions?

Each reported transaction involved the acquisition of 7 partnership shares and 7 matching shares, at a price of £18.0296 per Ordinary Share of 31¼ pence each under GSK’s Share Reward Plan.

On what date and market did the GSK (GSK) insiders acquire these shares?

The acquisitions took place on September 9, 2026, and were conducted on the London Stock Exchange (XLON), as disclosed for each reported person.

What type of equity instrument was involved in GSK (GSK) insiders’ acquisitions?

The transactions involved Ordinary Shares of 31¼ pence each, ISIN GB00BN7SWP63, acquired under GSK’s Share Reward Plan by the listed senior managers and the person closely associated with a manager.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 10:31 AM Accepted by SEC EDGAR 09/11/2026 - 10:30 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Neil Falkingham
b)	Position/status	PCA of Lynn Baxter (President, Europe)
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company’s Share Reward Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£18.0296	7 (partnership shares)
			£18.0296	7 (matching shares)
		d)	Aggregated information
Aggregated volume Price	14 Ordinary Shares £18.0296
e)	Date of the transaction	2026-09-09
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: September 11, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc